# PBA failure diagnostic: three-run MPDS analysis v1

## Status

- Frozen configuration: `pba_failure_diagnostic_n3_v1`
- Model/backend: Vertex AI `gemini-2.5-pro`
- Temperature: 0.5
- Structure: two personas, three debate rounds, final moderator synthesis
- Independent new runs: 3/3 COMPLETE
- Historical `Auto_Debate_With_Summary.txt`: preserved but not injected and not counted as a replicate
- Only authorized input correction: `K3[Co(CN)6]2` to `K3[Co(CN)6]`

## Execution audit

| Replicate | Attempted calls | Successful calls | API errors | Validation regenerations | Runtime (s) | Final characters |
|---:|---:|---:|---:|---:|---:|---:|
| 1 | 11 | 11 | 0 | 2 | 602.85 | 10,310 |
| 2 | 9 | 9 | 0 | 0 | 500.96 | 11,833 |
| 3 | 11 | 9 | 2 | 0 | 538.98 | 9,455 |

The two errors in replicate 3 were transient Vertex AI HTTP 429 responses. The unchanged request subsequently succeeded under the frozen retry policy. Across all runs there were 27 successful logical MPDS calls, two additional successful citation-validation regenerations, and two failed transient attempts.

Usage metadata summed over successful calls:

- Prompt tokens: 2,320,655
- Candidate/output tokens: 44,022
- Thoughts tokens: 68,877
- Total tokens: 2,433,554
- Cached-content tokens reported: 131,027

## Prespecified bottleneck coding

Only each run's final moderator synthesis was coded. Debate turns and persona-generation text were not used for the consensus decision.

| Replicate | Rank-1 category | Secondary categories | Constraint assessment |
|---:|---|---|---|
| 1 | Nucleation/growth control | Washing, filtration, drying | Major violation: invented citrate and changed the goal to a PBA-citrate lithium-anode protective layer |
| 2 | Nucleation/growth control | Filtration and drying | Partial scope drift into anode architecture and electrochemical testing |
| 3 | Washing/solvent exchange | Nucleation/growth, aging/crystallinity, surfactant stabilization | Partial scope drift, but the stated PBA chemistry was retained |

### Formal result under the frozen rule

The broad category **nucleation or growth control** was Rank 1 in 2/3 runs and therefore meets the prespecified category-level consensus rule.

This is not an exact intervention consensus. The proposed remedies varied across syringe-pump addition, temperature, pH, reactant ratio, surfactant handling, and advanced mixing. No single synthesis-variable modification was independently selected in at least 2/3 final syntheses with the same operating value.

All three runs also recommended gentler post-processing, particularly avoiding vacuum filtration/excessive ethanol washing and using centrifugation. However, this was not Rank 1 in 2/3 runs and must be reported as a cross-run secondary convergence rather than the prespecified primary consensus.

## Scientific interpretation boundary

The batch establishes stochastic diagnostic reproducibility only at a broad category level. It does not establish that nucleation/growth was the actual cause of the observed morphology. Replicate 1 is materially unreliable for recipe selection because it invented citrate and changed the scientific objective. Replicates 2 and 3 also show domain drift caused by the lithium-metal evidence persona. Therefore the broad 2/3 category result should not be presented as validated causal diagnosis.

No modified recipe should be claimed as selected by this batch alone. Before a prospective intervention, one additional decision is required:

1. If testing the formal Rank-1 category, specify one controlled nucleation/growth variable with a known original baseline (for example, syringe-pump feed rate or aging temperature), and change only that factor.
2. If prioritizing the strongest concrete cross-run recommendation, split one synthesis batch after the 24 h aging step and compare the original work-up against a predefined gentle work-up. This tests post-processing but must be labeled a secondary-convergence experiment, not the Rank-1-consensus intervention.

In either design, XRD and SEM acceptance criteria must be written before viewing the results, and the original and modified samples should be prepared from the same precursor batch where feasible.
